Cargando…
FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes
AIMS/HYPOTHESIS: Fibroblast growth factor 21 (FGF21) is considered to be a promising therapeutic candidate for the treatment of type 2 diabetes. However, as FGF21 levels are elevated in obese and diabetic conditions we aimed to test if exogenous FGF21 is sufficient to prevent diabetes and beta cell...
Autores principales: | Laeger, Thomas, Baumeier, Christian, Wilhelmi, Ilka, Würfel, Josefine, Kamitz, Anne, Schürmann, Annette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448882/ https://www.ncbi.nlm.nih.gov/pubmed/28770320 http://dx.doi.org/10.1007/s00125-017-4389-x |
Ejemplares similares
-
FGF21, not GCN2, influences bone morphology due to dietary protein restrictions
por: McNulty, Margaret A., et al.
Publicado: (2019) -
Adiponectin release and insulin receptor targeting share trans-Golgi-dependent endosomal trafficking routes
por: Rödiger, Maria, et al.
Publicado: (2017) -
Estradiol-dependent and independent effects of FGF21
in obese female mice
por: Jakovleva, T.V., et al.
Publicado: (2022) -
CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms
por: Satoh, Aoi, et al.
Publicado: (2020) -
GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice
por: Schwenk, Robert W., et al.
Publicado: (2014)